JCM
ADMA icon

Jacobi Capital Management’s ADMA Biologics ADMA Stock Holding History

Jacobi Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-800
Closed -$1K – 1377
2021
Q1 		$1K Sell
800
-1,300
-62% -$2.98K ﹤0.01% 1279
2020
Q4 		$4K Buy
2,100
+500
+31% +$1.05K ﹤0.01% 1030
2020
Q3 		$4K Buy
+1,600
New +$4.39K ﹤0.01% 967

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Jacobi Capital Management's ADMA Position: Q2 2021 in Review

Jacobi Capital Management sold out of ADMA Biologics (ADMA) in Q2 2021, closing a stake of 800 shares — an estimated $1K sold.

Jacobi Capital Management first reported a position in ADMA in Q3 2020 and held it in 3 quarters. The position peaked at $4K in Q4 2020. 90 funds tracked by Wall St. Rank hold ADMA as of Q2 2021.

  • Jacobi Capital Management reported no remaining ADMA Biologics position as of Q2 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 800 ADMA Biologics shares in Q2 2021, an estimated $1K.
  • Jacobi Capital Management first reported a position in ADMA Biologics in Q3 2020 and held it in 3 quarters.
  • Jacobi Capital Management's ADMA Biologics position peaked at $4K in Q4 2020.
  • 90 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2021.

Based on Jacobi Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.